Brian M. Culley - Mar 31, 2022 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role: President and CEO, Director
Signature: /s/ Brian M. Culley
Stock symbol: LCTX
Transactions as of: Mar 31, 2022
Transactions value $: $1,564
Form type: 4
Date filed: 4/4/2022, 04:05 PM
Previous filing: Mar 28, 2022
Next filing: Jun 30, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LCTX	Common Shares, no par value	Options Exercise		+15.5K	+19.01%		96.7K	Mar 31, 2022	Direct	F1, F2
transaction	LCTX	Common Shares, no par value	Tax liability	-$8.23K	-5.34K	-5.52%	$1.54	91.4K	Mar 31, 2022	Direct	F2, F3
transaction	LCTX	Common Shares, no par value	Purchase	$9.79K	+6.4K	+7%	$1.53	97.8K	Mar 31, 2022	Direct	F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LCTX	Restricted Stock Units	Options Exercise	$0	-15.5K	-50%	$0.00	15.5K	Mar 31, 2022	Common Shares	15.5K	$0.00	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis.
F2	Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report.
F3	Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.
F4	The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.52 to not more than $1.54. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.
F5	The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter.